TruthArchive.ai - Related Video Feed

Some antiparasitic drugs like mabendazole and ivermectin have shown effectiveness against certain cancers. Combining these drugs with others has led to the disappearance of solid tumors in some patients. It's not a single drug but a combination approach that yields results.

Ivermectin may have potential in fighting cancer by stopping the growth or killing certain cancer cells. Research suggests it could be effective against various cancers like breast, prostate, stomach, and others by inducing natural cell death. It is even used alongside chemotherapy for breast cancer. Consult your doctor before using Ivermectin. For more cancer-fighting tips, visit ehealthandu.com.

Ivermectin, a 62-year-old drug, has received a Nobel Prize for its unique properties. It has been found to block 8 pathways to cancer, making it a valuable repurposed drug in cancer treatment.

Ivermectin is claimed to be a "miraculous drug" that works for COVID-19 and influenza, potentially including H5N1. It has reportedly cleared psoriasis and Lyme disease in some patients. Repurposed drugs like ivermectin, initially designed for one purpose, are now being used for other conditions, including stage four cancer. Topical ivermectin cream is FDA-approved for rosacea, but horse paste is stronger and can treat inflammatory or autoimmune skin conditions, cystic acne, eczema, and skin cancers. Testimonials suggest that applying horse paste twice daily can cause lesions from basal cell carcinoma, squamous cell carcinoma, and melanoma to shrink and disappear within a couple of months. One patient reported that ivermectin applied to a tongue cancer caused the lesion to shrink. Women have also reported that it shrinks breast lumps and cysts. Oral ivermectin may help with autoimmune conditions like rheumatoid arthritis and juvenile rheumatoid arthritis. Low doses of 12-24mg may be effective for inflammatory conditions.

Ivermectin is a versatile drug with antiviral and anti-inflammatory properties that stimulate healing processes like autophagy and improve the microbiome. It is effective for early COVID treatment and vaccine injuries, and is affordable as a generic drug. Despite misconceptions, it is not a horse dewormer and has been available for as little as 2¢ per tablet through the WHO.

I found over 100 scientific papers showing Ivermectin's potential against cancer, primarily from preclinical studies. Researchers are puzzled by how this anti-parasitic drug, which has been effective for decades, can also treat cancer. Ivermectin is off patent, meaning there's little financial incentive for big pharma to invest in its research. Notably, Ivermectin can kill cancer stem cells, reverse chemotherapy resistance, and enhance the effectiveness of both chemotherapy and radiation. Patients combining Ivermectin with these treatments have shown remarkable results, including significant tumor reductions. After two years of research, I now treat over 1,000 cancer patients with Ivermectin and other anti-parasitic drugs. The recent mention by Mel Gibson about friends curing stage 4 cancer with these treatments highlights the growing awareness of this approach.

Researchers in Melbourne may have discovered a potential cure for COVID-19 using a cheap and widely available head lice treatment called Ivermectin. Monash University's Dr. Kylie Wagstaff and her team found that Ivermectin can kill SARS-CoV-2 cells in a petri dish. This treatment has also shown effectiveness against other viruses like HIV, influenza, dengue fever, and Zika. While promising, it's important to note that Ivermectin is typically used as a horse dewormer.

Fenbendazole is an overlooked cancer drug with at least 12 proven anti-cancer mechanisms. It disrupts microtubule polymerization, induces cell cycle arrest, blocks glucose transport, increases tumor suppressor levels, inhibits cancer cell viability, migration, and invasion, induces apoptosis, autophagy, and necrosis, and inhibits angiogenesis and drug resistance. Mebendazole, a similar drug, is already approved by the FDA and in clinical trials for brain and colon cancers. However, there are no Fenbendazole clinical trials for cancer, likely because it is cheap, safe, and effective. Big pharma may not see a profit margin in it, which raises concerns about their motives. This highlights the issue of a society designed to make people sick, with pharmaceutical companies profiting from remedies.

An article published in 2023 on desertreview.com (not peer reviewed) gathers doctors’ experiences with high-dose ivermectin in cancer. Dr. Tess Lohrey from the World Council for Health described a case of an ovarian metastatic cancer patient who took 'a fairly low dose, only twelve milligrams per day' with chemo, where 'CA-one 125 levels dropped from two eighty eight down to 22' and a 'shocking response to therapy.' Dr. Landryto recounted that a colleague with terminal gallbladder cancer 'started taking a high dose of daily ivermectin for fourteen months and her terminal gallbladder cancer completely resolved and disappeared.' Oscar Nasu, with neck tumor and cannonball lung metastases, took 'two point four mgkgday for three months'; 'the lung metastases shrank' and 'he no longer needed pain medication'; he is 'now on two point four five mgkgday' with no toxicity.

Ivermectin, a 62-year-old drug, has been found to have multiple uses. It received a Nobel Prize for its unique abilities, including blocking 8 pathways to cancer. As a result, Ivermectin is now being repurposed as a treatment for cancer patients.

Ivermectin has shown effectiveness in preventing COVID-19 infection, as evidenced by a trial in Argentina where 800 healthcare workers were prophylaxed and none got sick, compared to 58% of those who were not given Ivermectin. It has also demonstrated antiviral activity and has been proven effective as a prophylaxis agent in four large randomized controlled trials. In early outpatient treatment, it reduces the need for hospitalization and death, as shown in three randomized controlled trials and multiple case series. In hospitalized patients, Ivermectin has consistently shown lower mortality rates in four randomized controlled trials. It has already won the Nobel Prize in Medicine in 2015 for its impact on global health.

Ivermectin and mebendazole may disrupt cancer cell metabolism and glioma growth. Ivermectin blocks tumor cells from generating energy through oxidative phosphorylation, inhibits cancer stem cells, and disrupts glucose uptake. Mebendazole interferes with microtubule formation in glioma cells, induces apoptosis, and crosses the blood brain barrier. These drugs are backed by emerging science and used in terrain-based cancer protocols. When combined with fasting, oxygen therapy, and targeted nutrition, they may help flip the metabolic switch and support the body's natural healing power. The speaker claims this is how they overcame stage four brain cancer. The speaker is offering their complete healing protocol for free to those who comment "protocol."

Two patients with advanced cancer saw improvements after taking Ivermectin. The first patient, with stage 4 prostate cancer, experienced a decrease in PSA levels and improvement in symptoms. The second patient, diagnosed with esophageal tumors, saw the tumors disappear after taking Ivermectin. Both patients showed positive outcomes from using Ivermectin for their cancer treatment.

A man diagnosed with terminal colon cancer saw significant improvement after taking Ivermectin alongside chemotherapy. His CEA levels dropped rapidly, and the number of tumors in his liver decreased from 25 to 3. Despite eventually succumbing to liver failure, his wife credits Ivermectin for extending his life beyond the initial prognosis. This anecdotal story highlights the potential benefits of Ivermectin in cancer therapy.

Ivermectin, a 62-year-old drug, has been recognized with a Nobel Prize for its unique properties. It effectively blocks 8 pathways to cancer, making it a valuable repurposed drug for cancer patients.

We discovered that Ivermectin can kill COVID-19 in primate cells. A single dose of the drug stopped the virus from replicating within 48 hours. Human trials are on the horizon, as the drug has been safely used for decades. Repurposing existing drugs like Ivermectin can speed up development by utilizing known safety profiles and administration methods. We are working on determining if these benefits can translate to treating COVID-19 in humans.

Ivermectin is taken seriously by oncology in the UK and has shown anti-cancer activity, along with other drugs like thalidomide, CBD, and artemisinins. Ivermectin has multiple anti-cancer mechanisms and is given to millions worldwide, reportedly saving two million people a year from blindness. Mebendazole and febendazole, similar anti-parasitics, also have crossover links. Anecdotal evidence suggests these are used when conventional therapies fail. Ivermectin has few side effects at doses several times higher than normal, while mebendazole may cause liver toxicity, so intermittent use is recommended. A concoction of both is used to extend cancer treatment efficacy. Studies are needed to determine if there is real benefit, identify which people respond, determine the best management protocol and dose, and create a database of when ivermectin works. Oncology is using very high doses compared to normal. Intermittent use may be better than constant exposure. Formal studies are needed to determine if intermittent ivermectin at normal doses with mebendazole/febendazole is better than continuous high-dose ivermectin.

Ivermectin, known for its use in treating COVID-19, has also shown promise in treating aggressive cancers like glioblastomas, stage 4 breast and colon cancers, pancreatic cancers, gallbladder cancers, renal cancers, and melanomas. Research suggests that higher doses of Ivermectin can halt the growth and metastasis of these cancer cells, inducing apoptosis and autophagy to kill them. It is worth considering Ivermectin as a potential treatment for these turbo cancers, in addition to its effectiveness against viral outbreaks.

Ivermectin, a 62-year-old drug, has been found to have multiple uses. It received a Nobel Prize for its unique abilities, including blocking eight pathways to cancer. As a result, Ivermectin is now being repurposed as a treatment for cancer patients.

In 1970, a Japanese biochemist named Satoshi Omorra discovered a bacterium with intriguing effects against roundworm and shared it with American colleague William Campbell of Merck. Campbell used the bacterium to create ivermectin, released by Merck in 1980. Ivermectin proved extremely effective against river blindness (onchocerciasis), a disease caused by a parasitic worm that affected Central and South America and much of Africa. With ivermectin, river blindness has been largely eliminated in the Americas and greatly reduced in Africa. Billions of doses have been administered; it is listed among the World Health Organization’s essential medicines. Merck’s patent expired in 1996; the drug is cheap to produce, globally available in various formulations, and, at normal dosages, has no important side effects. In 2015, Omurra received the Nobel Prize for Medicine, shared with Campbell. Fast forward to early 2020, when the COVID-19 pandemic spread. Scientists searched for drugs with antiviral activity, and Monash University in Australia conducted a literature search that found ivermectin had shown activity against Zika, West Nile, and influenza. They performed experiments and found that ivermectin displays remarkable activity against SARS-CoV-2 in vitro, reporting a 5,000-fold reduction in viral levels after a single treatment without cytotoxicity, and proposed a mechanism for this effect. Around the same time, two American scientists noted that ivermectin was used as prophylaxis against river blindness in Africa and examined whether widespread ivermectin prophylaxis correlated with COVID-19 rates. They found that countries with extensive ivermectin prophylaxis had significantly lower COVID-19 rates. In Miami, Dr. Jean Jacques Reiter, a critical care and pulmonary specialist, treated COVID-19 patients with ivermectin after being urged by a patient’s son. He reported rapid improvement: the patient’s FiO2 requirements declined within 48 hours, and she was discharged within about a week. Reiter treated many patients with ivermectin and published a June 2020 preprint; he later testified before a Senate committee about his experiences. He stated that among hundreds of outpatients treated by his team, only two were admitted to the hospital; neither died or required intubation. Uncontrolled studies on ivermectin as prophylaxis and treatment circulated globally. A daughter described a care-home incident in Ontario, where residents on a floor receiving high-dose ivermectin for scabies reportedly had no COVID-19 infections among residents, even as staff on that floor became infected. In New York, Pierre Corry teamed with Reiter and Paul Merrick to form the Frontline COVID-19 Critical Care Alliance (FLCCC). In October 2020, the FLCCC released the Eye Mask Plus protocol, centering on ivermectin for prevention and treatment, and published a meta-analysis reviewing nine studies on prophylaxis and 12 studies on treatment, including seven randomized trials, all showing ivermectin’s superiority to controls. They presented figures showing reduced mortality and case rates associated with ivermectin use in various regions, including Peru, Mexico (Chiapas), and Argentina (healthcare workers). On December 8, 2020, FLCCC members appeared before a Senate subcommittee, with testimony claiming mountains of data showing ivermectin’s miraculous effectiveness and requesting the NIH to review their data. The transcript asserts widespread suppression of ivermectin information by mainstream media (New York Times, AP), big tech (YouTube, Twitter, Facebook), and the NIH. It alleges the NIH COVID-19 treatment guidelines panel, established in April 2020, largely recommended against early treatment and promoted remdesivir instead, even though remdesivir’s mortality impact was unproven and the World Health Organization advised against its use for improving survival. The panel’s treatment recommendations (as of 01/03/2021) are cited, highlighting monoclonal antibodies for early patients and no other treatments, except for remdesivir for deteriorating patients. Fauci publicly touted remdesivir’s endpoint as time to recovery, with the primary endpoint reportedly changed mid-trial from mortality to time to recovery, raising concerns about impartiality. The transcript traces remdesivir's production by Gilead Sciences and notes financial ties: seven panel members disclosed funding from Gilead; two of the three panel chairs received Gilead support, and Clifford Lane (one co-author on a remdesivir study) was closely connected to the study, with undisclosed ties among other authors. It argues these ties could impact decision-making and bias toward remdesivir over cheaper, repurposed drugs like ivermectin. The narrative then contrasts the U.S. approach with Uttar Pradesh, India, which authorized ivermectin as prophylaxis and treatment in August 2020. In January 2021, Uttar Pradesh reported near-zero COVID-19 deaths, while the United States faced ongoing high mortality, suggesting potential differential outcomes if ivermectin had been broadly authorized. The closing remarks emphasize the suffering caused by COVID-19 and its broad impacts on families and society.

Chemotherapy is claimed to be a hoax and scam by big pharma to profit from suffering people. It allegedly prolongs life by only two to three months and may reduce life expectancy for some cancers like gastric cancer. Chemotherapy is also said to help cancer spread and activate cancer stem cells. Chemotherapy drugs can cost patients over $100,000 a year, leading to financial problems for 50-60% of patients. Ivermectin combined with mebendazole or fenbendazole is suggested as a potentially effective first-line therapy for cancer. Testing over-the-counter medications and cheap prescriptions is recommended as well.

Ivermectin, a Nobel Prize-winning anti-parasitic drug, has been vilified. Merck, who held the patent until 1996, claims it doesn't work for COVID-19. However, Merck has a 50/50 partnership with Moderna on mRNA cancer vaccines. Because Merck will make billions on mRNA cancer vaccines, they have no interest in investigating ivermectin for cancer. There is evidence that high-dose ivermectin is effective in treating many types of cancers.

The speaker focuses on treating stage four cancer patients, often with late diagnoses. They use ivermectin combined with fenbendazole or mebendazole, both antiparasitics, even in early-stage breast cancer cases before surgery. The speaker claims that stage four cancers, including pancreatic, ovarian, and melanoma, have responded, with some patients becoming cancer-free. Tumors reportedly shrink significantly within months when patients take ivermectin and mebendazole before surgery. The speaker notes that ivermectin and fenbendazole are inexpensive, off-patent drugs, but customs in British Columbia and Mississauga are allegedly confiscating packages. A published paper supports the use of ivermectin and fenbendazole in cancer treatment. The speaker treated a friend of Mel Gibson, who then shared the story on Joe Rogan's podcast. Ivermectin is described as a chemo and radio sensitizer. The speaker faced backlash from a pancreatic cancer support group for sharing a patient's story. The speaker claims to have patients in hospice who are now cancer-free and one patient who was offered medical assistance in dying but is now cancer-free. The speaker recounts a case where a patient with terminal melanoma and liver failure stabilized and improved with ivermectin and fenbendazole. Oncologists are portrayed as limited to expensive, profitable treatments.

- It acts on these signaling pathways called PAC-one and ACT and MTOR and WNT pathways, these are pathways that are involved in tumor proliferation, tumor growth. - ivermectin inhibits multiple of these pathways that inhibit tumor growth, tumor proliferation, leads to cell cycle arrest, and it also inhibits metastases and the ability of the tumors to create blood vessels for themselves. - Then ivermectin also acts on cancer stem cells. It inhibits cancer stem cells. - They're involved in metastases, and they're involved in cancer recurrence. - cancer stem cells tend to be resistant to chemo. And then your cancer comes roaring back because these cancer stem cells start proliferating again. - So it inhibits cancer stem cells, very important. - Ivermectin also reverses multi drug resistance. So if you develop resistance to certain chemotherapy, Ivermectin will reverse it and Ivermectin acts in combination with chemo or radiation therapy. - Guzzo 2002 safety study: "the conclusion was that ivermectin was generally well tolerated with no indication of CNS toxicity." - up to two milligrams per kilogram per day.

Ivermectin, the controversial anti-parasitic drug, has shown potential in stopping the growth or killing certain cancer cells. Research suggests that it may be effective against various types of cancer, including breast, prostate, stomach, colon, liver, lung, kidney, and leukemia. Ivermectin induces apoptosis, or natural cell death, in cancer cells. It is even being used alongside chemotherapy for breast cancer. However, it is important to consult with your doctor before considering Ivermectin for any purpose. For more information on fighting cancer, you can watch a lecture by Dr. Shintani at ehealthandu.com. This is Dr. Chintani, a board-certified MD and nutritionist trained at Harvard, signing off for your health.